We are live on ! Find out more
IPHA

Innate Pharma
IPHA

9 hedge funds and large institutions have $179K invested in Innate Pharma in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

0.08% less ownership

Funds ownership: 0.19% → 0.11% (-0.08%)

10% less funds holding

Funds holding: 10 → 9 (-1)

37% less capital invested

Capital invested by funds: $282K → $179K (-$103K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
3
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$15.6K
2
Citadel Advisors
Citadel Advisors
Florida
+$4.77K
3
GI
GAMMA Investing
California
+$2.48K
4
PS
Principal Securities
Iowa
+$91

Top Sellers

Rank Fund Capital Flow
1
ETC
Exchange Traded Concepts
Oklahoma
-$112K
2
Millennium Management
Millennium Management
New York
-$7.44K
3
UBS Group
UBS Group
Switzerland
-$6.18K
4
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
-$416
5
TRCT
Tower Research Capital (TRC)
New York
-$5

IPHA Hedge Fund Activity: Q2 2025 in Review

9 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q2 2025, worth a combined $179K — down 37% from $282K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of IPHA and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 3 added.

The largest buyer was Morgan Stanley, adding an estimated $15.6K. The largest seller was Exchange Traded Concepts, exiting entirely with an estimated $112K sold.

  • 9 institutional investors held Innate Pharma (IPHA) as of Q2 2025, down from 10 in Q1 2025.
  • Funds reported $179K of Innate Pharma stock for Q2 2025, down 37% quarter-over-quarter.
  • 1 fund opened new Innate Pharma positions in Q2 2025 and 2 closed out, a net change of -1 holder.
  • The largest Innate Pharma buyer in Q2 2025 was Morgan Stanley, an estimated $15.6K added.
  • The largest Innate Pharma seller in Q2 2025 was Exchange Traded Concepts, an estimated $112K sold.

Based on aggregated 13F filings for Q2 2025.